Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.